Detail akcie Lineage Cell Rg online

Business Summary: Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Lineage Cell Therapeutics Inc revenues increased 20% to $7.9M. Net loss increased from $15.3M to $64.4M. Revenues reflect Royalties and license fees increase of 71% to $1.6M, Collaboration revenues increase of 11% to $6.3M. Higher net loss reflects Unrealized marketable securities increase from $21K to $37M (expense), Research and development - Balancing val increase of 5% to $9M (expense).